Inhibition of cGMP-phosphodiesterase-5 by biflavones of Ginkgo biloba

  • Planta Med. 2006 Apr;72(5):468-70. doi: 10.1055/s-2005-916236.
Mario Dell'Agli  1 Germana V Galli Enrica Bosisio
Affiliations
  • 1. Department of Pharmacological Sciences, Faculty of Pharmacy, Milan, Italy. [email protected]
Abstract

Ginkgo biloba dimeric Flavonoids (GBDF) were shown to inhibit cAMP phosphodiesterase activity and to promote vasorelaxation. In particular, amentoflavone exhibited endothelium-dependent relaxation of rat aorta rings via enhanced generation and/or increased biological activity of nitric oxide, leading to elevated cGMP levels. The aim of this study was to investigate whether GBDF were able to inhibit cGMP-specific phosphodiesterase-5 (PDE5) as well. Human recombinant PDE5A1 was prepared by expression of the full-length cDNA of PDE5A1 in COS-7 cells. The PDE activity was determined in the presence of Biflavones at 0.1-100 microM. All Biflavones inhibited PDE5A1 in a concentration-dependent fashion, ginkgetin being the most potent (IC50 = 0.59 microM). The ability to inhibit the enzyme followed this order: ginkgetin > bilobetin > sciadopitysin > amentoflavone > sequoiaflavone. These data suggest that GBDF could exert a vasodilating effect through a mechanism independent of NO release.

Products